Suggested Reading Comi G. Early treatment. Neurol Sci . 2006;27 Suppl 1:S8-12. Galetta SL. The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study). J Neuroophthalmol . 2001;21(4):292-295. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNb-1b trial. Neurology . 2012;78(17):1315-1322. Granberg T, Martola J, Kristoffersen-Wiberg M, et al. Radiologically isolated syndrome—incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review. Mult Scler . 2013;19(3):271-280. Kang H, Metz L, Traboulsee A, et al. Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes. Mult Scler . 2013 Sep 2 [Epub ahead of print]. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler . 2008;14(9):1157–1174. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol . 2011;69(2):292-302. Tedeholm H, Lycke J, Skoog B, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler . 2013;19(6):765-774.